 |
| Attached files |
| File | Filename |
| EX-32.01 - CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002. - CHINA PEDIATRIC PHARMACEUTICALS, INC. | exhibit_32-1.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R50.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R47.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R20.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R38.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R27.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R58.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R10.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R5.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R41.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R26.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R21.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R51.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R34.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R16.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R14.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R13.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R60.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R15.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R19.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R23.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R11.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R12.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R4.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R18.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R1.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R17.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R3.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R7.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R24.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R36.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R22.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R35.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R59.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R6.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R45.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R2.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R53.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R40.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R32.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R8.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R31.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R30.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R44.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R56.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R28.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R29.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R43.htm |
| EXCEL - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | Financial_Report.xls |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R9.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R52.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R37.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R42.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R25.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R57.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R33.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R46.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R55.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R48.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R54.htm |
| XML - IDEA: XBRL DOCUMENT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | R39.htm |
| EX-31.02 - CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - CHINA PEDIATRIC PHARMACEUTICALS, INC. | exhibit_31-2.htm |
| EX-31.01 - CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO EXCHANGE ACT RULES 13A-14(A) AND 15D-14(A), AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002. - CHINA PEDIATRIC PHARMACEUTICALS, INC. | exhibit_31-1.htm |
| 10-Q - SEPTEMBER 30, 2011 QUARTERLY REPORT - CHINA PEDIATRIC PHARMACEUTICALS, INC. | cpdu_2012sept30-10q.htm |
v2.4.0.6
|
Income Taxes - USA Income Taxes (Details) (USA, USD $)
|
3 Months Ended |
9 Months Ended |
|
Sep. 30, 2012
|
Sep. 30, 2011
|
Sep. 30, 2012
|
Sep. 30, 2011
|
|
USA
|
|
|
|
|
| Income (loss) before taxes from USA |
|
$ 241,250 |
$ (9,693) |
$ 5,762,500 |
| Statutory tax rate |
34.00% |
34.00% |
34.00% |
34.00% |
| Income tax at statutory tax rate |
|
82,025 |
(3,296) |
1,959,250 |
| Permanent tax difference due to derivative income |
|
(82,025) |
|
(1,959,250) |
| Increase in valuation allowance |
|
|
3,296 |
|
| Income tax expense at effective rate |
|
|
|
|
| X |
- Definition
The component of income tax expense for the period representing amounts paid or payable (or refundable) as determined by applying the provisions of enacted federal tax law to the domestic taxable Income or Loss from continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 289
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Current Tax Expense (or Benefit)
-URI http://asc.fasb.org/extlink&oid=6509736
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section 50
-Paragraph 9
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6907707&loc=d3e32639-109319
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.7)
-URI http://asc.fasb.org/extlink&oid=6889476&loc=d3e330036-122817
Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 6
-Section I
-Paragraph Question 1-7
Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 109
-Paragraph 45
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(h))
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e23780-122690
Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 08
-Paragraph h
-Article 4
+ Details
| Name: |
us-gaap_CurrentFederalTaxExpenseBenefit |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
debit |
| Period Type: |
duration |
|
| X |
- Definition
The amount of net gains and losses recognized in income during the period on derivative instruments designated and qualifying as hedging instruments in fair value hedges and related hedged items designated and qualifying in fair value hedges, on derivative instruments designated and qualifying as hedging instruments in cash flow hedges, and on derivative instruments not designated as hedging instruments.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4C
-Subparagraph (a),(c),(d),(e)
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5624171-113959
Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 205G
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Statement of Financial Accounting Standard (FAS)
-Number 133
-Paragraph 44C
-Subparagraph b
-LegacyDoc This reference is SUPERSEDED by the Accounting Standards Codification effective for interim and annual periods ending after September 15, 2009. This reference is included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.
Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 815
-SubTopic 10
-Section 50
-Paragraph 4A
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=7476318&loc=SL5618551-113959
+ Details
| Name: |
us-gaap_DerivativeInstrumentsGainLossRecognizedInIncomeNet |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
credit |
| Period Type: |
duration |
|
| X |
- Definition
Total increases or decreases in allowances and reserves, the valuation and qualifying accounts that are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6881521&loc=d3e24092-122690
+ Details
| Name: |
us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease |
| Namespace Prefix: |
us-gaap_ |
| Data Type: |
xbrli:monetaryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
This web site and associated pages are not associated with, endorsed by, or sponsored by CHINA PEDIATRIC PHARMACEUTICALS, INC. and has no official or unofficial affiliation with CHINA PEDIATRIC PHARMACEUTICALS, INC.
Based on public records. Inadvertent errors are possible. Faqs.org does not guarantee the accuracy or timeliness of any information on this site. Use at your own risk.
This website is not associated with the SEC
Some parts © 2013 Advameg, Inc.
|
|